CureVax, LLC, is an immunotherapy company dedicated to developing Viral oncolysate vaccine against melanoma. A viruslysed tumor cell vaccine is an active immunotherapeutic agent against tumors in mammals.
CureVax, LLC, is developing a recombinant, IL-2-secreting vaccinia virus-based, multivalent antigen retrieval platform using five proprietary patient derived melanoma cells.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Under the Vaccine prepration method, tumor cells are removed from a mammal, the cells are cultured in a culture medium and infected with live vaccinia virus. Viral oncolysis occurs during incubation and the resulting viral oncolysate, after extraction, may be injected into mammals to stimulate the immune response mechanism.
Recover your password.
A password will be e-mailed to you.